Potential Effect of Vortioxetine on Restless Leg Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Restless legs syndrome (RLS) is a chronic progressive movement disorder characterized by abnormal sensations, especially at rest and at night, as the need and urge to move the lower extremity. It has been reported that RLS severity and frequency increase in patients with anxiety and depression. It has been reported that serotonin-noradrenaline reuptake inhibitors such as venlafaxine and selective serotonin reuptake inhibitors such as citalopram, fluoxetine, paroxetine, and sertraline can cause RLS symptoms. No adverse effects of vortioxetine on RLS have been reported in the literature. In this case series, we report the effect of vortioxetine in patients with RLS with symptoms of depression and anxiety. In this case series, the effect of adding vortioxetine to treatment on RLS symptoms is reported in 7 patients (5 female). After the use of vortioxetine, 5 of 7 patients’ symptoms regressed without the need to start a separate drug for primary movement disorder. In conclusion, we believe that studies should be conducted to investigate the efficacy of vortioxetine in the treatment of RLS. Therefore, randomized controlled studies are needed to determine the effect and safety of vortioxetine on RLS symptoms.
Abstract
Restless legs syndrome (RLS) is a chronic progressive movement disorder characterized by abnormal sensations, especially at rest and at night, as the need and urge to move the lower extremity. It has been reported that RLS severity and frequency increase in patients with anxiety and depression. It has been reported that serotonin-noradrenaline reuptake inhibitors such as venlafaxine and selective serotonin reuptake inhibitors such as citalopram, fluoxetine, paroxetine, and sertraline can cause RLS symptoms. No adverse effects of vortioxetine on RLS have been reported in the literature. In this case series, we report the effect of vortioxetine in patients with RLS with symptoms of depression and anxiety. In this case series, the effect of adding vortioxetine to treatment on RLS symptoms is reported in 7 patients (5 female). After the use of vortioxetine, 5 of 7 patients’ symptoms regressed without the need to start a separate drug for primary movement disorder. In conclusion, we believe that studies should be conducted to investigate the efficacy of vortioxetine in the treatment of RLS. Therefore, randomized controlled studies are needed to determine the effect and safety of vortioxetine on RLS symptoms.
참고문헌 (29)
- Allen RP, "Restless legs syndrome", Willis-Ekbom disease diagnostic criteria : Updated International Restless Legs Syndrome Study Group(IRLSSG)consensus criteria--history, rationale, description, and significance, 2014, pp.15, 860~873
- Chokroverty S, "Editor’s corner : Restless legs syndrome, a common disease uncommonly diagnosed", Sleep Med, 4, pp.91~93 (2003)
- Sevim S, "Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey", Neurology, 61, pp.1562~1569 (2003)
- Banno K, "Restless legs syndrome in 218 patients : Associated disorders", Sleep Med, 1, pp.221~229 (2000)
- Patrick L, "Restless legs syndrome : Pathophysiology and the role of iron and folate", Altern Med Rev, 12, pp.101~112 (2007)
- Kubo K, "Relationship between quality of life and restless legs syndrome among a community-dwelling population in Japan", Neuropsychiatr Dis Treat, 12, pp.809~815 (2016)
- Allen RP, "Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome", Am J Med, 120(1 Suppl 1), pp.S13~S21 (2007)
- Allen RP, "Restless leg syndrome", Willis-Ekbom disease pathophysiology, 2015, pp.10, 207~214
- Merlino G, "Restless legs syndrome:Diagnosis, epidemiology, classification and consequences", Neurol Sci, 28(Suppl 1), pp.S37~S46 (2007)
- Baier PC, "Circadian variation in restless legs syndrome", Sleep Med, 8, pp.645~650 (2007)
- Trenkwalder C, "Comorbidities, treatment, and pathophysiology in restless legs syndrome", Lancet Neurol, 17, pp.994~1005 (2018)
- Bailey AL, "Selective serotonin reuptake inhibitor", serotonin-norepinephrine reuptake inhibitor use as a predictor of a diagnosis of restless legs syndrome, 2016, pp.22, 263~269
- Happe S, "Restless legs syndrome in patients with depressive disorders", Somnologie, 16, pp.183~188 (2012)
- Winkelmann J, ""Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome", J Neurol, 252, pp.67~71 (2005)
- Becker PM, "Mood disorders in restless legs syndrome(Willis-Ekbom disease)", J Clin Psychiatry, 75, pp.e679~e694 (2014)
- Hornyak M, "Depression in restless legs syndrome. Pathogenesis, assessment, and implications for treatment", Nervenarzt, 80, pp.1160~1166 (2009)
- Salagre E, "Vortioxetine: A new alternative for the treatment of major depressive disorder", Rev Psiquiatr Salud Ment(Engl Ed), 11, pp.48~59 (2018)
- Stahl SM, "Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent(MMA) : Enhancing serotonin release by combining serotonin(5HT)transporter inhibition with actions at 5HT receptors(5HT1A, 5HT1B, 5HT1D, 5HT7 receptors)", CNS Spectr, 20, pp.93~97 (2015)
- Ece Buyuksandalyaci Tunc, "Vortioxetine Induced Hypomania: A Case Presentation and Review of the Literature", Clinical Psychopharmacology and Neuroscience, 20(2), pp.394~397 (2022), 대한정신약물학회[DOI]
- Hye Won Jeong, "Vortioxetine Treatment for Depression in Alzheimer’s Disease: A Randomized, Double-blind, Placebo-controlled Study", Clinical Psychopharmacology and Neuroscience, 20(2), pp.311~319 (2022), 대한정신약물학회[DOI]
- Mørk A, "P. 2. e. 002 Vortioxetine(Lu AA21004), a multimodal antidepressant : Differentiation from current antidepressants in animal models of depression", Eur Neuropsychopharmacol, 23, pp.S392~S393 (2013)
- Bang-Andersen B, "In successful drug discovery", pp.189~214 (2016), John Wiley & Sons
- Jacobsen P, "Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults : A randomized, controlled trial", J Sex Med, 16, pp.1638~1649 (2019)
- Earley CJ, "Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome(Willis-Ekbom Disease)", Sleep Med, 15, pp.1288~1301 (2014)
- Stiasny-Kolster K, "Validation of the"L-DOPA test"for diagnosis of restless legs syndrome", Mov Disord, 21, pp.1333~1339 (2006)
- Buchfuhrer MJ, "Strategies for the treatment of restless legs syndrome", Neurotherapeutics, 9, pp.776~790 (2012)
- Aurora RN, "Update to the AASM Clinical Practice Guideline : "The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012 : Practice parameters with an evidence-based systematic review and meta-analyses"", Sleep, 35, pp.1037~ (2012)
- Garcia-Borreguero D, "Guidelines for the first-line treatment of restless legs syndrome", Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation : A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation, 2016, pp.21, 1~11
- Heim B, "Augmentation and impulsive behaviors in restless legs syndrome : Coexistence or association?", Neurology, 87, pp.36~40 (2016)